Clinical validation of MR‐generated synthetic CT by MRCAT for brain tumor radiotherapy
Journal of Applied Clinical Medical Physics · 2025-01 · 26 (1)
DOI: 10.1002/acm2.14494 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Applied Clinical Medical Physics, online erschienen am 13.12.2024. Verfasst von Tyrone Tsz Yeung Yip und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated, Brain Neoplasms, Radiotherapy Dosage. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Research Fund, Innovation and Technology Support Programme, Health and Medical Research Fund.
Abstract (Originalsprache)
Objective
MRI is an emerging modality in radiotherapy (RT). Accuracy synthetic CT is the prerequisite for implementing MR‐only RT planning. This study validated the commercial algorithm of MR for calculating attenuation (MRCAT) in terms of image quality and dosimetric agreement.
Methods
Brain tumor cases with 18 treated using intensity‐modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT), and 15 treated using stereotactic radiosurgery (SRS) were analyzed. Synthetic CTs were resampled referencing planning CT. Treatment plan calculated on planning CT was recalculated on resampled MRCAT. Image quality of selected metrics and dosimetric agreements were assessed by dose‐volume‐histogram and 3D gamma analysis.
Results
For IMRT/VMAT and SRS cases, mean error were 23.42 ± 1.05 and 28.39 ± 3.17 HU; mean absolute error were 38.03 ± 1.42 and 52.36 ± 2.63 HU; root mean squared error were 89.09 ± 6.65 and 108.38 ± 12.23 HU; peak signal‐to‐noise ratio were 29.11 ± 0.60 and 27.65 ± 0.59 dB; and structural similarity index measures were 0.88 ± 0.00 and 0.70 ± 0.01 respectively. No significant differences were identified for DVH metrics accounting the target coverage. Most OARs did not have significant dose deviation, except left lens with 0.70% higher in D‐mean after recalculation ( p < 0.001). For criteria of 3 mm/3%, 2 mm/2%, and 1 mm/1%, gamma passing rates for IMRT/VMAT were 99.92%, 99.42%, and 96.47%, while SRS were 99.86%, 99.52%, and 97.57% respectively. Correlation between passing rate and image quality metrics was established in IMRT/VMAT cases, with higher similarity yield better dosimetric agreement between planning and synthetic CT.
Conclusion
This study has validated the MRCAT for clinical use in terms of comparable image quality and dosimetric agreement with planning CT. Further case selection and MR‐compatible immobilization device would be required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Technology and Informatics, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hong Kong, Hong Kong.
Förderung
- General Research Fund
- Innovation and Technology Support Programme
- Health and Medical Research Fund
- National Natural Science Foundation of China Young Scientist Fund
Zitieren
APA
Yip, T. T. Y., Li, Z., & Li, T. (2025). Clinical validation of MR‐generated synthetic CT by MRCAT for brain tumor radiotherapy. Journal of Applied Clinical Medical Physics, 26(1). https://doi.org/10.1002/acm2.14494
Vancouver
Yip TTY, Li Z, Li T. Clinical validation of MR‐generated synthetic CT by MRCAT for brain tumor radiotherapy. Journal of Applied Clinical Medical Physics. 2025;26(1). doi:10.1002/acm2.14494
BibTeX
@article{Yip2025,
author = {Yip, Tyrone Tsz Yeung and Li, Zhichun and Li, Tian},
title = {Clinical validation of MR‐generated synthetic CT by MRCAT for brain tumor radiotherapy},
journal = {Journal of Applied Clinical Medical Physics},
year = {2025},
volume = {26},
number = {1},
doi = {10.1002/acm2.14494}
}
EUVIMED